May 28, 2020 Bio/Pharma/CRO Clinical Research/Diagn. Microscopy

Roche initiates phase III clinical trial of Actemra/RoActemra plus remdesivir in hospitalised patients with severe COVID-19 pneumonia

Basel, 28 May 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the initiation of a global phase III, randomised, double-blind, multicentre study (REMDACTA) to evaluate the safety and efficacy of Actemra/RoActemra plus the investigational antiviral remdesivir, versus placebo plus remdesivir in hospitalised patients with severe COVID-19 pneumonia, in collaboration with Gilead Sciences, Inc.  Read more

May 27, 2020 Bio/Pharma/CRO Microscopy

Roche’s Port Delivery System with ranibizumab shows positive phase III results in neovascular age-related macular degeneration

Basel, 27 May 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from the phase III Archway study, evaluating Port Delivery System with ranibizumab (PDS) in people living with neovascular or “wet” age-related macular degeneration (nAMD). PDS is a permanent refillable eye implant, approximately the size of a grain of rice,... Read more

May 22, 2020 Clinical Research/Diagn. Life Science Tools M&A, Partnerships

Roche acquires Stratos Genomics to further develop DNA based sequencing for diagnostic use

Genomics insights generated through sequencing an individual’s DNA play a critical role in personalised healthcare and clinical diagnostics of the future Roche is committed to developing a nanopore sequencer with the aim of providing the healthcare community and ultimately patients with faster and more accurate medical information to predict risk and detect disease This investment... Read more

May 22, 2020 Product Launch

New longer-term data reinforce safety of Roche’s satralizumab in adults and adolescents with neuromyelitis optica spectrum disorder

Pooled data from two pivotal Phase III open-label extension (OLE) studies show satralizumab was well-tolerated as a monotherapy or in combination with baseline immunosuppressive therapy in people with neuromyelitis optica spectrum disorder (NMOSD) Adolescents treated with the same dosing and frequency demonstrated a benefit-risk profile generally consistent with the adult population  Current dosing achieved sustained... Read more

May 19, 2020 Acad, Gov/Utilities

FDA approves Roche’s Tecentriq as a first-line monotherapy for certain people with metastatic non-small cell lung cancer

Tecentriq’s fourth indication in metastatic non-small cell lung cancer and fifth indication in lung cancer overall in the US  Approval based on the Phase III IMpower110 study showing Tecentriq demonstrated a significant overall survival benefit in people with high PD-L1 expression compared with chemotherapy Basel, 19 May 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY)... Read more

May 14, 2020 Clinical Research/Diagn. PAI Top-10

Roche to present first clinical data on novel anti-TIGIT cancer immunotherapy tiragolumab at ASCO

Phase II CITYSCAPE trial shows promising results adding tiragolumab to Tecentriq in people with PD-L1-positive metastatic non-small cell lung cancer Full results will be presented in an oral abstract session at the ASCO20 Virtual Scientific Program organised by the American Society of Clinical Oncology (ASCO) Basel, 14 May 2020 – Roche (SIX: RO, ROG; OTCQX:... Read more

May 11, 2020 Uncategorized

Changes to the Roche Enlarged Corporate Executive Committee

Basel, 11 May 2020 Roche today announced that Michael Varney (1958) Ph.D., and Head of Genentech Research and Early Development (gRED) since 2015, will retire from the company at the end of July.  Aviv Regev (1971), Ph.D., and currently Chair of the Faculty, Core Institute Member, and member of the Executive Leadership Team of the... Read more

May 7, 2020 Product Launch

New data at the ASCO20 Virtual Scientific Program reflects Roche’s commitment to accelerating progress in cancer care

First clinical data from tiragolumab, Roche’s novel anti-TIGIT cancer immunotherapy, in combination with Tecentriq® (atezolizumab) in patients with PD-L1-positive metastatic non-small cell lung cancer (NSCLC) Updated overall survival data for Alecensa® (alectinib), in people living with anaplastic lymphoma kinase (ALK)-positive metastatic NSCLC Key highlights to be shared on Roche’s ASCO virtual newsroom, 29 May 2020,... Read more